DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the RPG LIFE SCIENCES LTD (RPGLIFE) share price today?

RPG LIFE SCIENCES LTD (RPGLIFE) is trading at ₹2,859.8 on the NSE, down 2.13% on the day. Source: DocStoX.

What is the PE ratio of RPG LIFE SCIENCES LTD?

RPG LIFE SCIENCES LTD has a price-to-earnings (PE) ratio of 25.8 in the Healthcare sector.

What is the market capitalisation of RPG LIFE SCIENCES LTD?

RPG LIFE SCIENCES LTD has a market capitalisation of approximately ₹4,724 crore.

RPG LIFE SCIENCES LTD

RPGLIFE·NSE·Healthcare

₹2,859.80▼ -62.10 (-2.13%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹2826.10

₹2939.90

52W₹1733

₹299489%

Open

₹2915.00

High

₹2939.90

Low

₹2826.10

Prev Close

₹2921.90

Volume

16.9K

VWAP

₹2875.45

Snapshot

Key fundamentals

Market Cap

₹4,724 Cr

P/E Ratio

25.81Fair

P/B Ratio

7.26

EPS

₹110.79

Book Value

₹366.01

ROE

19.03%Strong

ROCE

33.00%Efficient

Dividend Yield

0.90%

Debt / Equity

0.03Low

Face Value

₹8.00

52W High

₹2993.80

52W Low

₹1733.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹590

▼ 79.4%downside

Trading at ₹2,860 — 79% above our estimate

BearFair valueBull

₹488₹590₹955

/100

Business quality — Solid

Growth 0Profitability 85Efficiency 58Valuation 79

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 33%)
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹366 book

₹488

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹955

Analyst target

No analyst coverage

—

Blended fair value₹590

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 33%)
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

25.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

19.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

33.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.03Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹4,724 Cr

P/B

7.26

EPS

₹110.79

Div Yield

0.90%

What changed

Recent changes

Foreign investors-0.1% stake last quarter
Domestic institutions+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 25.8×

Growth

Steady

+11% rev CAGR

Profitability

Excellent

19.0% ROE

Financial health

Rock solid

D/E 0.03

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.9%

Turnover₹486.84L Cr

Trades2,846

VWAP₹2875.45

Face value₹8.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+11.3%

+12.7%

10Y

+9.8%

Profit

+19.2%

+23.6%

10Y

+25.4%

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 28.8%

Watch-outs

Cons

Stock is trading at 7.81 times its book value
Debtor days have increased from 46.5 to 60.2 days.
Working capital days have increased from 44.6 days to 63.7 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.13 pts; domestic institutions added 0.41 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

73.0%0.00

Public

15.0%-0.19

FII / FPI

0.9%-0.13

DII

7.5%+0.41

Others

3.8%

Total shareholders

25,282-623 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.95%

FII0.87%

DII7.45%

Public14.98%

Others3.75%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]